• About us
  • Science and Pipeline
  • Investors
  • Contact us
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us

Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026

Oct 6, 2026 | Press Releases

Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.comKing of Prussia, Pennsylvania–(Newsfile Corp. – October 6, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a...

Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference

Oct 5, 2026 | Press Releases

Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania–(Newsfile Corp. – October 5, 2026) – Phio Pharmaceuticals Corp. (NASDAQ:...

Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference

Sep 23, 2026 | Press Releases

Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania–(Newsfile Corp. – September 23, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical...

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Sep 14, 2026 | Press Releases

Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b TrialKing of Prussia, Pennsylvania–(Newsfile Corp. – September 14, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA...

Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Sep 11, 2026 | Press Releases

Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762King of Prussia, Pennsylvania–(Newsfile Corp. – September 11, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company...

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

Aug 11, 2026 | Press Releases

PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.King of Prussia, Pennsylvania–(Newsfile Corp. – August 11, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a...
« Older Entries
Next Entries »

Recent Posts

  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
  • Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
  • Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
  • Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Recent Comments

No comments to show.
Email Alerts

Stay up to date on news and investor alerts

Sign up now

© 2026 Phio Pharmaceuticals

  • Follow
  • Follow
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us